Search Results
Your search for The ,The matches 33911 pages
Showing 1601 - 1650Use of Enzalutamide in Nonmetastatic Castration-Sensitive Prostate Cancer With Biochemical Recurrence
On November 16, 2023, the androgen receptor inhibitor enzalutamide was approved for use in patients with nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.1 Supporting Efficacy Data Approval was based on the EMBARK trial (ClinicalTrials.gov...
The High Cost of Oral Agents for Relapsed and Refractory Multiple Myeloma
Late in 2023, Richardson et al shared the results of a phase I/II clinical trial (ClinicalTrials.gov identifier NCT03374085). They concluded that the “all-oral combination of mezigdomide plus dexamethasone showed promising efficacy in patients with heavily pretreated multiple myeloma.”1 Mezigdomide ...
Ken Kato, MD, PhD, on Advanced Esophageal Cancer: Biomarker Analyses From CheckMate 648
Ken Kato, MD, PhD, of Japan’s National Cancer Center Hospital, discusses the first comprehensive findings on biomarkers from the CheckMate 648 study. These results further corroborate the clinical efficacy of nivolumab plus chemotherapy and nivolumab plus ipilimumab in the first-line treatment of...
Long-Term Follow-up of KEYNOTE-590: Benefit of Pembrolizumab Plus Chemotherapy Affirmed in Advanced Esophageal Cancer
Long-term follow-up of the phase III KEYNOTE-590 trial has confirmed the benefit of pembrolizumab plus chemotherapy in advanced esophageal cancer. As compared with chemotherapy alone, after a median follow-up of almost 59 months, patients treated with the chemoimmunotherapy combination were three...
First-Line Nivolumab Plus Ipilimumab Shows Benefit in Metastatic Colorectal Cancer Subset
In the phase III CheckMate 8HW trial, previously untreated patients with microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) metastatic colorectal cancer derived significant benefit from an immunotherapy doublet of nivolumab plus ipilimumab in the first-line setting, which...
Expert Point of View: Rory M. Shallis, MD
Rory M. Shallis, MD, Assistant Professor of Medicine (Hematology) at Yale School of Medicine, shared his thoughts on the use of revumenib in histone-lysine N-methyltransferase 2A-rearranged (KMT2A-rearranged) leukemia, as reported in the phase II AUGMENT-101 trial. In an interview with The ASCO...
AUGMENT-101 Trial: Menin Inhibitor Revumenib Shows Activity in KMT2A-Rearranged Acute Leukemia
In heavily pretreated patients with a challenging type of acute leukemia, the menin inhibitor revumenib demonstrated clinically meaningful activity, including high rates of response and measurable residual disease (MRD) negativity, according to the efficacy and safety results of the phase II...
Michael K. Gibson, MD, PhD, on Esophageal Cancer: Expert Commentary on Two Key Studies
Michael K. Gibson, MD, PhD, of Vanderbilt University Medical Center, discusses phase III findings on chemotherapy plus camrelizumab in the ESCORT-NEO trial of patients with resectable esophageal squamous cell carcinoma; and phase III SKYSCRAPER-08 results on first-line tiragolumab plus atezolizumab ...
New Director of the University of Hawaii Cancer Center, Naoto T. Ueno, MD, PhD, FACP, Is Also a Two-Time Cancer Survivor
In this installment of The ASCO Post ’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Naoto T. Ueno, MD, PhD, FACP, Director of the University of Hawaii Cancer Center. Along with his duties leading the cancer center, Dr. Ueno leads translational breast cancer research...
Antiemetic Strategies for Patients Receiving Highly Emetogenic Chemotherapy
In an Indian single-center phase III trial reported in The Lancet Oncology, Bajpai et al found that low-dose olanzapine was noninferior to standard-dose olanzapine plus triple antiemetic therapy in terms of antiemetic efficacy and reduced daytime somnolence in patients with solid tumors receiving...
Celebrating Excellence: Matthijs Oudkerk, PhD, MD, MSc, Honored for Contributions to Cancer Prevention and Research
The Prevent Cancer Foundation has honored Matthijs Oudkerk, PhD, MD, MSc, with the prestigious James L. Mulshine, MD, International Leadership Award. Dr. Oudkerk is Professor of Radiology at the University of Groningen and Chief Scientific Officer of the Institute for Diagnostic Accuracy in the...
Novel Molecular Twin Tool May Improve Precision Medicine Care in Patients With Pancreatic Cancer
The novel artificial intelligence (AI)-based Molecular Twin Precision Oncology Platform may be capable of identifying biomarkers that may outperform the standard test for predicting pancreatic cancer survival, according to a recent study published by Osipov et al in Nature Cancer. Background...
Factors Influencing Selection of Active Surveillance for Low-Risk Prostate Cancer
Investigators may have uncovered some of the factors associated with the selection of active surveillance over surgery or radiation therapy in patients with low-risk prostate cancer, according to a recent study published by Xu et al in Cancer. Background Guidelines for low-risk prostate cancer that ...
Beyond Lung Cancer: Leveraging Machine Learning Techniques to Understand Other Diseases
Although computed tomography (CT) screening has emerged as an essential tool for the early detection of lung diseases, there is still a broad range of potential improvements to be made. According to recent research, understanding the patterns of onset for earlier prediction of disease may be...
Tackling the Challenges of Oncology Workforce Shortages, Increased Patient Demand, and Rising Costs of Care
In May 2023, The ASCO Post launched a new feature, View From the Top: The Future of Cancer Care Delivery, which explores how leaders in oncology are developing strategies to ensure continued innovative oncology care in an ever-changing health-care environment. In this installment, Guest Editor Jame ...
NETTER-2: Lu-177 Dotatate for Advanced Gastroenteropancreatic Neuroendocrine Tumors
Results from the first phase III clinical trial evaluating radioligand therapy in the first-line setting demonstrated that treatment with lutetium Lu-177 dotatate significantly improved progression-free survival and objective response rates in patients with high-grade gastroenteropancreatic...
Adding Immunotherapy-Based Combination to TACE Improves Progression-Free Survival in HCC
The addition of durvalumab and bevacizumab to transarterial chemoembolization (TACE) significantly improved progression-free survival in patients with unresectable hepatocellular carcinoma who were eligible for embolization. According to the study authors, this is the first trial to demonstrate...
Final Overall Survival Analysis of CLEAR/KEYNOTE-581: Lenvatinib/Pembrolizumab vs Sunitinib in First-Line Treatment of Advanced RCC
As reported in the Journal of Clinical Oncology by Robert J. Motzer, MD, and colleagues, the prespecified final overall analysis of the phase III CLEAR/KEYNOTE-581 trial supported a benefit of lenvatinib/pembrolizumab vs sunitinib in the first-line treatment of advanced renal cell carcinoma. The...
Standard vs Histology-Tailored Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma
In an expanded cohort of a European trial reported in the Journal of Clinical Oncology, Alessandro Gronchi, MD, and colleagues found that histology-tailored neoadjuvant chemotherapy with trabectedin was noninferior in terms of disease-free survival to standard neoadjuvant anthracycline/ifosfamide...
FDA Approves Erdafitinib for Locally Advanced or Metastatic Urothelial Carcinoma
On January 19, the U.S. Food and Drug Administration (FDA) approved the FGFR inhibitor erdafitinib (Balversa) for adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, as determined by an FDA-approved companion diagnostic test, whose...
Novel CAR NK-Cell Therapy May Offer Benefit in Patients With B-Cell Malignancies
A novel chimeric antigen receptor (CAR) natural killer (NK)-cell therapy may be effective at treating patients with relapsed or refractory B-cell malignancies, according to a novel study published by Marin et al in Nature Medicine. Study Methods and Results In the new phase I/II trial, researchers...
Do Patients With Molecular MRD Detected After Colorectal Cancer Surgery Benefit From Adjuvant Chemotherapy?
Following surgery to remove a colorectal tumor, patients may have molecular measurable residual disease (MRD). Circulating tumor DNA (ctDNA), or liquid biopsy, may be used to detect molecular MRD in patients who underwent surgery for colorectal cancer and to determine whether they may benefit from...
Role of Postoperative ctDNA in Patients With Low-Risk Stage IIA Colon Cancer
The role of circulating tumor DNA (ctDNA), or liquid biopsy, as a predictive tool to guide and monitor cancer treatment remains unclear, after the first prospective randomized phase II trial evaluating clearance of ctDNA in patients with stage II colon cancer receiving adjuvant chemotherapy did not ...
Combining PD-L1 and TIGIT Inhibitors Plus Chemotherapy in Esophageal Cancer
Results from the phase III SKYSCRAPER-08 study found that combining PD-L1 and T-cell immunoglobulin and ITM domain (TIGIT) inhibitors plus chemotherapy in the first-line setting extended survival in an Asian population of patients with metastatic or locally advanced esophageal squamous cell...
Prevalence of Substance Use Disorders Among U.S. Adult Cancer Survivors
In a study reported in JAMA Oncology, Jones et al found a prevalence of active substance use disorders of 3.8% among U.S. adult survivors of solid tumor cancers, with higher rates among those with head/neck, esophageal/gastric, and cervical cancers as well as melanoma. Study Details The study used...
Use of Antiviral Therapy and 10-Year Outcomes in Resected Hepatitis-Related Hepatocellular Carcinoma
In a retrospective cohort study reported in the Journal of Clinical Oncology, Daniel Q. Huang, MBBS, and colleagues found that the use of antiviral therapy was associated with improved overall survival among patients with hepatitis B virus (HBV)- or hepatitis C virus (HCV)-related hepatocellular...
Overall Survival and Long-Term Outcomes in the monarchE Trial
As reported in the Journal of Clinical Oncology by Priya Rastogi, MD, and colleagues, an interim analysis of overall survival in the phase III monarchE trial showed no significant benefit with the addition of 2 years of adjuvant abemaciclib to endocrine therapy in patients with hormone...
Addition of Cetuximab Maintenance to First-Line FOLFIRI/Cetuximab in RAS/BRAF Wild-Type Colorectal Cancer
As reported in the Journal of Clinical Oncology by Pinto et al, the Italian phase III ERMES trial showed that the addition of cetuximab maintenance to eight cycles of first-line FOLFIRI (fluorouracil, leucovorin, and irinotecan) plus cetuximab did not achieve noninferiority in terms of...
Follicular Lymphoma: Long-Term Follow-up of Rituximab Dosing Strategies Among Patients With Low Tumor Burden
As reported in the Journal of Clinical Oncology by Brad S. Kahl, MD, and colleagues, long-term follow-up of the phase III Eastern Cooperative Oncology Group RESORT study (E4402) showed that rituximab maintenance did not improve overall survival vs rituximab retreatment in rituximab induction...
Combating Racial and Ethnic Disparities in Precision Medicine for Colorectal Cancer
Investigators may have uncovered molecular evidence of racial disparities in the receipt of precision medicine, according to a recent study published by Yamada et al in npj Precision Oncology. Background Colorectal cancer is the third most common cancer type diagnosed in both male and female...
Investigators Highlight Characteristics Potentially Linked to Improved CAR T-Cell Therapy Outcomes in Large B-Cell Lymphoma
Investigators have assessed whether specific tumor characteristics were associated with improved outcomes in patients with large B-cell lymphoma who received chimeric antigen receptor (CAR) T-cell therapy, according to a recent study published by Locke et al in Nature Medicine. The findings may...
Novel PI3K Inhibitor as Part of Triplet Improves Outcomes in Hormone Receptor–Positive, HER2-Negative Breast Cancer
The addition of inavolisib to first-line treatment with palbociclib plus fulvestrant more than doubled progression-free survival in patients with recurrent PIK3CA-mutated, hormone receptor–positive, HER2-negative advanced breast cancer, according to a late-breaking primary analysis of the phase III ...
American Cancer Society Annual Report Shows Cancer Mortality Still Declining, but Cancer Incidence Is Projected to Top 2 Million
Although overall cancer mortality has continued to decline, resulting in over 4 million fewer deaths in the United States since 1991, increasing incidence for 6 of the top 10 cancers pushed the projected number of new diagnoses to over 2 million (2,001,140) for the first time, according to the...
Normal Risk Ovarian Screening Study: Long-Term Update
As reported in the Journal of Clinical Oncology by Han et al, the 21-year update of the Normal Risk Ovarian Screening Study (NROSS) has shown that the NROSS screening strategy remains effective for the detection of ovarian cancer and detection at early disease stages. Study Details The NROSS...
Undocumented Cost-of-Care Discussions: A Missed Opportunity in Cancer Treatment
A recent study underscored the need for integrating cost-of-care conversations in cancer treatment. Results of the population-based analysis, presented at the 2023 ASCO Quality Care Symposium,1 showed that only about 25% of patients with newly diagnosed advanced non–small cell lung cancer (NSCLC)...
Cannabis Use During Pregnancy May Be Linked to CNS Cancers in Children
Researchers may have identified an association between certain types of childhood cancers and cannabis use among pregnant patients, according to a recent study published by Wimberly et al in Cancer Epidemiology, Biomarkers & Prevention. The findings add specificity to the potential harms of...
DXH9 Depletion May Expose Small Cell Lung Cancer Tumors to Immune System Attack
Researchers may have identified a novel genetic mechanism capable of making small cell lung cancer tumors more susceptible to an attack by the immune system, according to a new study published by Murayama et al in Cancer Discovery. The findings could lead to the development of new therapeutics to...
Medicaid Expansion May Improve Postsurgical Survival Outcomes in Patients With NSCLC
Investigators have found that Medicaid expansion under the Affordable Care Act may be associated with a reduced risk of early mortality following surgical resection in patients with non–small cell lung cancer (NSCLC), according to a recent study published by Nogueira et al in JAMA Network Open. The ...
Repotrectinib in ROS1 Fusion–Positive NSCLC
As reported in The New England Journal of Medicine by Alexander Drilon, MD, and colleagues, the phase I/II TRIDENT-1 trial showed the activity of the next-generation ROS1 tyrosine kinase inhibitor repotrectinib in patients with ROS1 fusion–positive non–small cell lung cancer (NSCLC) with no...
Use of Lower-Than-Recommended Doses of Immune Checkpoint Inhibitors in Various Tumor Types: Indian Study
In an Indian single-institution study reported in JCO Global Oncology, Patel et al found that use of lower-than-recommended doses of immune checkpoint inhibitors showed activity across various tumor types. As stated by the investigators: “The cost of immune checkpoint inhibitors limits their...
MRD Status and Outcomes With Obinutuzumab- and Rituximab-Based Treatment in Follicular Lymphoma
In an analysis from the phase III GALLIUM study reported in the Journal of Clinical Oncology, Pott et al identified measurable residual disease (MRD) status and related outcomes among patients receiving obinutuzumab- and rituximab-based treatment for previously untreated follicular lymphoma. Study...
FDA Approves Pembrolizumab Plus Chemoradiotherapy for FIGO 2014 Stage III–IVA Cervical Cancer
On January 12, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) with chemoradiotherapy for patients with International Federation of Gynecology and Obstetrics (FIGO) 2014 stage III–IVA cervical cancer. KEYNOTE-A18 Efficacy was evaluated in KEYNOTE-A18...
Obesity and a Precursor of Multiple Myeloma
Patients with obesity may be more likely to have monoclonal gammopathy of undetermined significance, according to a recent study published by Lee et al in Blood Advances. Background Monoclonal gammopathy of undetermined significance—a benign hematologic condition characterized by an abnormal...
Study Identifies Potential Variations in U.S. Health Insurance Coverage at Cancer Diagnosis by State
Investigators have uncovered substantial state variations in health insurance coverage among U.S. patients newly diagnosed with cancer, according to a recent study published by Hu et al in Health Affairs Scholar. Background Over the past decade, health insurance coverage—which has been found to be...
Hope S. Rugo, MD, on Triple-Negative Breast Cancer: Trial Update on Pembrolizumab Plus Olaparib vs Pembrolizumab Plus Chemotherapy
Hope S. Rugo, MD, of the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses data from the phase II KEYLYNK-009 study, which compared pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with pembrolizumab plus chemotherapy...
Ibrahim Aldoss, MD, on KMT2A-Rearranged Acute Leukemia: New Data on Revumenib Monotherapy
Ibrahim Aldoss, MD, of City of Hope National Medical Center, discusses phase II safety and efficacy results from the Augment-101 study. This trial showed that patients with heavily pretreated, relapsed or refractory KMT2-rearranged acute leukemia benefited from monotherapy with the menin-KMT2A...
Harinder Gill, MD, MBBS, on Acute Promyelocytic Leukemia: Assessing the Use of Oral Arsenic Trioxide, Retinoic Acid, and Ascorbic Acid
Harinder Gill, MD, MBBS, of The University of Hong Kong, discusses findings showing the use of an “AAA” regimen (pure oral arsenic trioxide combined with all-trans retinoic acid) in a risk-adapted strategy that minimized chemotherapy was highly effective and safe in patients with newly diagnosed...
Mazyar Shadman, MD, MPH, on Large B-Cell Lymphoma: Autologous Transplantation vs CAR T-Cell Therapy
Mazyar Shadman, MD, MPH, of the University of Washington, discusses new data suggesting that in patients with relapsed large B-cell lymphoma who achieve a complete response, treatment with autologous transplantation may be associated with a lower relapse rate and improved progression-free survival...
Jeffrey E. Rubnitz, MD, PhD, on Pediatric AML Outcomes and Racial Disparities
Jeffrey E. Rubnitz, MD, PhD, of St. Jude Children’s Research Hospital, discusses study findings suggesting that pharmacogenomic differences between Black and White patients should be considered when tailoring induction regimens to improve outcomes of all patients and bridge the racial disparity gap ...
Reshma Jagsi, MD, DPhil, on Early-Stage Breast Cancer: 5-Year Outcomes With Endocrine Therapy and Breast-Conserving Surgery
Reshma Jagsi, MD, DPhil, of Emory University Winship Cancer Institute, discusses the IDEA trial of endocrine therapy without radiotherapy after breast-conserving surgery for postmenopausal patients between the ages of 50 and 69 with stage I breast cancer. The regimen demonstrated a low risk of...
